Evotec SE to Announce Results for the First Nine Months 2026 on November 5, 2026

Original HTML

HAMBURG, Germany, Oct. 29, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) will hold a webcast and conference call to announce its financial results for the first nine months 2026 and provide a business update on Thursday, November 5, 2026. The conference call will be held in English.

Webcast details

Date: Thursday, November 5, 2026

Time: 2.00 pm CET (1.00 pm GMT, 8.00 am EST)

To join the audio webcast and to access the presentation slides, please register via this link.

The on-demand version of the webcast will be available on our website: www.evotec.com.

Conference call details

To join the conference call, please pre-register via this link. You will then receive a confirmation email with dedicated dial-in details such as telephone number, access code and PIN to access the call.

A simultaneous slide presentation for participants dialing in via phone is available under this link.

About Evotec SE

Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure â faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers' needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just â Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec's global team of around 4,500 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec.

Forward-looking statements

This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Investor Relations and Media Contact

Dr. Sarah Fakih

EVP Head of Global Communications & Investor Relations

[email protected]

SOURCE Evotec SE

Share this article

Class (B2B/B2C)

B2B

Ingest Status

Need Review

Dedupe hash

prn_302923251

Press Eligible

Yes

Press Eligible Reason

QA FAIL (need review): The target contains an unsupported factual claim that the webcast will be held in English (the source only specifies the conference call is in English), and the final paragraph is boilerplate corporate description from the source's About section with no news context.

Source Name

Unknown Company

Original Summary

<p>HAMBURG, Germany, Oct. 29, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) will hold a webcast and conference call to announce its financial results for the first nine months 2026 and provide a business update on Thursday, November 5, 2026. The conference call...</p>

Original Link

Original Source

Generated Article_json

{"target_audience": "b2b", "is_medical": false, "ai_generated_title": "Evotec to Report Nine-Month 2026 Results on November 5", "body_html": "<p><strong>HAMBURG -- [CURRENT_DATE] --</strong> Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) will publish its financial results for the first nine months of 2026 on Thursday, November 5, 2026, alongside a business update.</p><h5>Webcast and call start at 2.00 pm CET in English</h5><p>The session begins at 2.00 pm CET, which is 1.00 pm GMT and 8.00 am EST. Both the webcast and the conference call will be held in English.</p><p>The audio webcast comes with presentation slides, and participants must register in advance. A recording will be available on Evotec's website after the event.</p><h5>Dial-in participants must pre-register for access codes</h5><p>Callers must pre-register for the conference call. They will then receive a confirmation email containing the telephone number, access code and PIN. Participants dialing in by phone can follow a simultaneous slide presentation through a separate link.</p><h5>Revenue, Group EBITDA and unpartnered R&D expense are the metrics named</h5><p>Evotec's forward-looking statement refers to its expectations for revenues, Group EBITDA and unpartnered R&D expenses. The company notes that no assurance can be given that these expectations will prove correct. It also disclaims any obligation to update them publicly.</p><p>Evotec says it works with all Top 20 Pharma companies and more than 800 biotechs. It reports a portfolio of over 100 proprietary R&D assets, most of them co-owned, and around 4,500 employees across Europe and the U.S.</p>", "meta_description": "Evotec SE (NASDAQ: EVO) will publish nine-month 2026 results and a business update on Nov. 5 at 2.00 pm CET via English-language webcast and conference call.", "seo_keywords": "Evotec, Evotec SE, nine-month 2026 results, earnings call, NASDAQ EVO, Frankfurt EVT, drug discovery, business update, webcast", "companies": ["Evotec SE"], "industries": ["Biopharmaceuticals"], "markets_regions": ["Germany", "Europe", "United States"], "news_type": ["financial_disclosure", "earnings_announcement"], "products": [], "themes": ["investor_relations", "financial_reporting"], "events": ["Evotec First Nine Months 2026 Results Webcast"], "cta_text": "Register for the Evotec nine-month 2026 results webcast and conference call", "learn_more": "https://www.evotec.com", "fact_check": {"accuracy_score": 100, "legal_risk": "low", "corrections_made": [], "recommendation": "publish"}}

Content Hash (SHA-256, erste 32 hex)

32589645436152ce60f97213b452a224